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Background and aim: Caspase-cleaved cytokeratin 18 (CK18-Asp396) is a potential clini-
cally useful biomarker in liver disease as it is released from hepatocytes during apoptosis. In 
this study, we investigated serum CK18-Asp396 levels in chronic hepatitis B (CHB).
Patients and methods: Overall, 163 patients with CHB were included. Serum 
CK18-Asp396 levels were determined by enzyme-linked immunosorbent assay (ELISA), and 
results were related to steatosis grade, histological activity index, inflammation score, and 
METAVIR fibrosis grade as well as to viral load, serum levels of liver enzymes, and albumin. 
Receiver operating characteristic analysis was used to evaluate the diagnostic performance 
of serum CK18-Asp396 levels for assessing disease activity.
Results: A higher level of serum CK 18 concentrations was found in patients with significant 
inflammation vs no significant inflammation (378.5 [interquartile range {IQR}: 173.2–629.6] vs 
137.3 [87.5–197.7], P < 0.05; approximately threefold increase) and in patients with significant 
fibrosis vs no significant fibrosis (177.8 [IQR: 120.8–519.1] vs 142.7 [IQR: 88.8–214.4], P < 
0.05; 1.25-fold increase). There was no differential CK 18 level by degree of steatosis. CK 18 
was an independent predictor of significant inflammation with an 82% specificity and a 94% 
negative predictive value. We found the strongest correlation of CK 18 with alanine amino-
transferase and aspartate aminotransferase (both r = 0.52; P < 0.001), but less with albumin 
(r = -0.24; P < 0.05) and viral load (log) (r = 0.19; P < 0.05).
Conclusion: CHB appears to be accompanied by continuous high levels of hepatocyte apop-
tosis as judged from serum CK 18, suggesting that elimination of the infected compartment 
constitutes a defensive strategy against disease. Accordingly, CK 18 works as an independent 
predictor of significant inflammation with a high specificity.
Keywords: CHB, CK 18, apoptosis, steatosis, inflammation
Plain language summary
In recent years, it has become clear that serum levels of a fragment of cytokeratin 18 (the so-
called caspase-cleaved cytokeratin 18 [CK18-Asp396]) reflect the amount of programmed cell 
death in the liver. It remains, however, obscure whether programmed cell death is in general 
important during hepatitis B infection and specifically whether serum levels of CK18-Asp396 
can be a marker for disease severity in hepatitis B. In this study, we showed that liver inflam-
mation of hepatitis B is characterized by high levels of the so-called CK18-Asp396, and this 
novel marker for hepatitis B-associated inflammation is potentially superior to currently used 
serum markers.
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Introduction
Chronic hepatitis B (CHB) infection is a major public health 
problem, which affects more than 350 million people world-
wide.1 It is well known that CHB is associated with hepatic 
steatosis, inflammation, and fibrosis.2–5 Hence, histological 
examination is an integral part of evaluating CHB patients. 
Evaluation of the CHB-associated liver damage is critically 
important for making decisions in antiviral therapy and need 
for surveillance.6 Liver biopsy remains the golden standard 
in assessing the severity of inflammation and fibrosis.6,7 
However, the procedure is costly, sensitive to sampling errors, 
and a potential cause for complications.8 Therefore, a reliable 
noninvasive diagnostic tool is urgently needed.
An increasing number of studies have emerged to explore 
potential noninvasive tools. Given the importance of apopto-
sis in the development of chronic liver disease in general,9–11 
the importance of apoptosis in CHB remains unclear, and 
studies are hampered by the difficulty of distinguishing 
apoptosis in the hepatocyte compartment and the lymphocyte 
compartment. The former may represent the efforts of the 
body to limit the size of the infected compartment and may 
thus be associated with antiviral responses in lieu of viral 
clearance and consequently with aggravated inflammation 
and progression to hepatocellular carcinoma (HCC).12,13 
Apoptosis in the lymphocyte compartment is, however, asso-
ciated with reduced inflammatory activity.14 Hence, studies 
looking specifically at hepatocyte apoptosis are urgently 
needed to characterize the role of programmed cell death in 
CHB, and hepatocyte-specific apoptosis markers may also 
have substantial diagnostic value.
In this context, cytokeratin-18 (CK 18) is interesting. 
Expression of CK 18 is limited to certain endodermal deriva-
tives, but is most prominently expressed in hepatocytes.15 
During hepatocyte apoptosis, CK 18 is subject to specific 
cleavage by caspases, resulting in the release of neo-epitope 
(CK18-Asp396), which is not detectable in necrotic or vital 
cells.16 CK 18 is the best described hepatocyte-specific apop-
tosis marker,17 and many studies investigated the potential 
value of CK 18 as a noninvasive marker in predicting the 
severity of steatosis, inflammation, and fibrosis. Previous 
studies have shown that increased levels of CK18-Asp396 
are associated with CHB and related to the severity of steato-
sis.18–20 In addition, CK18-Asp396 can be a predictive marker 
for distinguishing between inactive carrier and HBeAg-
negative CHB,21 and CK 18 correlates with the presence 
of significant fibrosis in chronic hepatitis C,22 nonalcoholic 
fatty liver disease (NAFLD),23 and cirrhosis associated with 
CHB.24 Thus, CK 18 appears useful to  measure hepatocyte 
apoptosis in CHB and its measurement would allow making 
correlations between hepatocyte programmed cell death, 
inflammatory responses, and viral load, allowing assessment 
as to the extent to which hepatocyte apoptosis contributes to 
antiviral defense.
In this study, we measured CK18-Asp396 in a group of 
CHB patients in a well-characterized Dutch cohort which 
includes patients across all grades of steatosis, inflammation, 
and fibrosis. The results show that CK18-Asp396 is associ-
ated with hepatic inflammation and diagnostically useful for 
clinical determination of this condition. Furthermore, the 
results support the notion that hepatocyte apoptosis may con-
tribute to limiting the size of the virus-infected compartment.
Patients and methods
Patient selection
This retrospective study included 163 consecutive patients 
with CHB from 1985 to 2012 at the Erasmus University 
Medical Center in Rotterdam, the Netherlands. Three indi-
cations were defined as an end point in this study: steatosis 
grade, inflammation, and fibrosis. Steatosis was classified 
into the following groups according to Brunt score:25 <5%, 
normal; 5–33%, mild steatosis; 34–66%, moderate steatosis; 
>66%, severe steatosis. The inflammatory activity (grade) and 
the degree of hepatic fibrosis (stage) were assessed according 
to the modified histological activity index of Ishak system 
and METAVIR system (nil fibrosis, F0; mild fibrosis, F1; 
moderate fibrosis, F2; advanced fibrosis, F3; cirrhosis, F4), 
respectively.26,27 For the purpose of this study, inflammation 
was divided into two groups: significant inflammation (grade 
≥ 7) and nonsignificant inflammation (grade < 7). Similarly, 
fibrosis staging was divided into subgroups: significant 
fibrosis (stage ≥ 3) and nonsignificant fibrosis (stage < 3).7
This study was performed according to the guidelines of 
the Declaration of Helsinki and the principles of Good Clini-
cal Practice. Due to the retrospective nature of this study, the 
informed consent was not obtained from patients. Patients’ 
identities were not revealed in our study. This study was 
approved by the ethical review board of Erasmus Medical 
Center (Rotterdam, the Netherlands).28
Laboratory test
Serum level of CK 18 was measured by the  M30-Apoptosense 
enzyme-linked immunosorbent assay (ELISA) kit (VLVbio 
[Peviva], Nacka, Sweden) according to the manufacturer’s 
instructions, which have been well established to accurately 
measure CK18-Asp396.29 Each patient sample was measured 
in triplicate, and the absorbance value was determined by 
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microplate reader (FLUOstar Omega; BMG Labtech, De 
Meern, the Netherlands), according to the routine proce-
dures.30 In short, the ELISA measures apoptosis in CK 
18-positive cells, such as hepatocytes, with an antibody that 
specifically recognizes soluble caspase-cleaved CK 18.
Statistical analysis
Continuous variables were reported as mean (SD) or median 
(interquartile range [IQR]) according to data distribution, 
and categorical variables as percent. Quantitative variables 
were analyzed using Student’s t-test for normal distribution 
data or Mann–Whitney U test for highly skewed data. The 
eventual diagnostic predictor value was calculated by receiver 
operating curve (ROC). Youden index was used to deter-
mine the optimal cutoff value of CK 18. The probabilities 
of true positive (sensitivity) and true negative (specificity) 
were determined according to the calculated optimal cutoff 
value. The positive/negative likelihood ratio (LR+/LR-) 
was calculated by the following formula: LR+ = sensitivity/
(1 – specificity); LR- = (1 – sensitivity)/specificity. The area 
under the ROC curve (AUROC) was generated to assess the 
diagnostic performance of each independent predictor. ROC 
relevant analyses were performed by using pROC package.31 
Correlation was calculated using Spearman’s rank correla-
tion coefficient. All statistical analyses were performed in R 
software (version 3.2.0), and statistical significance was set 
at P < 0.05 (two-tailed).
Results
Patient characteristics
The characteristics of the patients are described in Table 1. 
The mean age of the 163 patients was 40 years old. In terms 
of inflammation, there were 22 patients with significant 
inflammation (grade ≥ 7), which accounted for 13% of total 
patients. As for fibrosis, there were 33 cases with significant 
fibrosis (advanced fibrosis or cirrhosis), accounting for 20% 
of patients. Finally, the grade of steatosis was considered as 
normal in 2 patients (1%), mild in 104 patients (64%), mod-
erate in 44 patients (27%), and severe in 13 patients (8%).
Elevated serum CK 18 levels in patients 
with significant inflammation and fibrosis
Figure 1 shows the serum CK 18 levels across patients when 
differentiated to steatosis grade, severity of inflammation, or 
fibrosis grade. When comparing steatosis grade, the differ-
ence in CK 18 serum levels was not significant (P > 0.05). 
However, there were significant differences in CK 18 levels 
among different grades of inflammation and fibrosis. Patients 
with significant inflammation had a higher CK 18 serum level 
than those with no significant inflammation (378.5 [IQR: 
173.2–629.6] vs 137.3 [87.5–197.7], P < 0.05; approximately 
threefold increase). Similarly, patients who presented with 
significant fibrosis had a higher CK 18 level than those with 
no significant fibrosis (177.8 [IQR: 120.8–519.1] vs 142.7 
[IQR: 88.8–214.4], P < 0.05; 1.25-fold increase). Correlation 
of CK 18 serum levels was analyzed with several other clini-
cal parameters recorded in this cohort (Table 2). In terms of 
biochemical parameters, the strongest correlation was with 
alanine aminotransferase (ALT) and aspartate aminotransfer-
ase (AST; both r = 0.52; P < 0.001), followed by a negative 
correlation with albumin (r = -0.24, P < 0.05) and a posi-
tive correlation with viral load (log) (r = 0.19, P < 0.05). No 
correlation with either age or body mass index (BMI) was 
found (P > 0.05). Among the histological parameters, CK 18 
correlated best with the grade of inflammation (r = 0.37; P < 
0.001), followed by the grade of fibrosis (r = 0.18; P < 0.05). 
No correlation with steatosis was found (P > 0.05). Through 
multivariate analyses, adjusting for age, BMI, viral load (log), 
ALT level, ASL level, and albumin level, it was demonstrated 
that CK 18 serum levels can act as an independent predictor 
of the presence of significant inflammation (P < 0.05), but 
not for significant fibrosis (P > 0.05).
Predictive value of CK 18 for significant 
inflammation
We then assessed the potential value of CK 18 as a diagnostic 
tool by estimating AUROC, sensitivity, and specificity. The 
AUROC of CK 18 for predicting significant inflammation 
was 0.81 (95% CI: 0.72–0.91; Figure 2). Sensitivity, speci-
ficity, positive/negative predictive values, and LR+/LR- are 
summarized in Table 3. Of note, all these values were calcu-
lated according to the optimal cutoff points of CK 18 levels: 
243.0 U/L. Although CK 18 had a low sensitivity of 68% 
and a very low positive predictive value of 37%, it showed a 
high specificity of 82% and a high negative predictive value 
up to 94%.
Discussion
The contemporary of biomedical literature supports the notion 
that CK18-Asp396 serum levels adequately reflect hepatocyte 
apoptosis.32 In our study, we exploited this notion to evaluate 
hepatocyte apoptosis in CHB, although we did not assess apop-
tosis directly. The study demonstrated, however, that CHB is 
indeed associated with CK18 release into the serum. As CK18 
levels showed strong correlations with significant inflamma-
tion and fibrosis, with liver enzymes but not with steatosis, our 
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results support the notion of CK18 being a marker for hepato-
cyte apoptosis. Especially, interesting are our results suggesting 
a diagnostic value of CK 18 serum levels for the identification 
of significant inflammation of the liver in CHB patients. The 
strong correlation with inflammatory responses suggests that 
hepatocyte apoptosis may serve as a strategy to limit the size 
of the chronic hepatitis B (HBV)-infected compartment, a 
notion possibly supported by the observation that viral load 
shows only weak correlation with CK18-Asp396 serum levels, 
possibly reflecting the functional effects of compartment size 
reduction. Future studies are necessary to substantiate this idea.
A previously published study suggested a combination 
of routine tests as noninvasive markers for liver inflam-
mation and fibrosis.7 In that report, a prediction model 
was suggested for the identification of significant liver 
inflammation combining age, HBV DNA levels, AST, 
and albumin. However, in the current study, CK 18 serum 
level was the single independent predictor based on our 
multivariate analysis. In terms of significant inflammation, 
CK 18 serum level was regarded as a good predictor with 
an 82% specificity and a 68% sensitivity. The apparent 
superiority of CK18-Asp396 serum level determination 
Table 1 Clinical characteristics of patients with CHB virus infection
Characteristics All patients  
(n = 163)
Significant 
inflammation  
(n = 22)
No significant 
inflammation  
(n = 141) 
Significant  
fibrosis  
(n = 33) 
No significant 
fibrosis  
(n = 130) 
Gender, n (%) 
Male 136 (83) 18 (18) 118 (84) 28 (85) 108 (83)
Female 27 (17) 4 (82) 23 (16) 5 (15) 22 (17)
Age, years
Mean (SD) 40.0 (11.5) 45.5 (13.1) 39.1 (11.0) 47.2 (12.1) 38.1 (10.6)
Median (IQR) 41.0 (31.0–48.0) 47.5 (35.3–55.8) 39.0 (31.0–46.0) 48.0 (39.0–56.0) 37.0 (30.3–45.8)
Race, n (%) 
Caucasian 84 (52) 12 (55) 72 (51) 18 (54) 66 (51)
Asian 51 (31) 8 (36) 43 (30) 11 (33) 40 (31)
African/Black 23 (14) 1 (5) 22 (16) 4 (12) 19 (15)
Other race 5 (3) 1 (5) 4 (3) 0 (0) 5 (4)
BMI
Mean (SD) 27.2 (4.1) 27.5 (4.0) 27.2 (4.2) 27.1 (3.3) 27.3 (4.3)
Median (IQR) 27.0 (24.8–29.8) 28.6 (25.6–30.1) 27.0 (24.8–29.8) 27.2 (24.8–29.2) 27.0 (24.8–29.8)
HBeAg status, n (%)
Positive 58 (36) 13 (59) 45 (32) 11 (33) 47 (36)
Negative 105 (64) 9 (41) 96 (68) 22 (67) 83 (64)
ALT, xULN, U/L 
Mean (SD) 2.3 (3.9) 3.2 (1.8) 2.2 (4.1) 2.4 (1.8) 2.3 (4.3)
Median (IQR) 1.5 (1.1–2.2) 2.8 (1.9–4.6) 1.4 (1.1–1.9) 1.8 (1.0–3.4) 1.5 (1.1–2.0)
AST, xULN, U/L
Mean (SD) 1.4 (1.2) 2.1 (0.9) 1.2 (1.2) 1.8 (1.1) 1.3 (1.2)
Median (IQR) 1.0 (0.8–1.4) 1.9 (1.5–2.6) 1.0 (0.8–1.2) 1.5 (1.0 –2.1) 1.0 (0.9–1.2)
ALK
Mean (SD) 79.9 (64.5) 85.6 (33.8) 78.9 (68.6) 82.4 (28.5) 79.2 (71.2)
Median (IQR) 72 (60.0–89.0) 72.0 (63.0–97.0) 71.0 (59.0–86.0) 75.0 (62.8–90.5 71.0 (59.0–84.0)
Albumin, g/L
Mean (SD) 45.0 (3.5) 42.4 (3.1) 45.5 (3.4) 42.8 (4.0) 45.7 (3.1)
Median (IQR) 45.0 (43.0–47.0) 42.5 (40.0–45.0) 46.0 (44.0–48.0) 44.0 (40.0–45.3) 46.0 (44.0–48.0)
Viral load (log) 
Mean (SD) 5.0 (2.9) 7.2 (1.9) 4.8 (2.9) 5.8 (2.4) 4.9 (3.0)
CK 18 serum level, U/L
Mean (SD) 206.6 (190.5) 404.8 (236.6) 175.7 (162.6) 321.3 (304.1) 177.5 (135.7)
Median (IQR) 150.6 (95.8–242.9) 378.5 (173.2–620.6) 137.3 (87.5–197.7) 177.8 (120.8–519.1) 142.7 (88.8–214.4)
Significant inflammation, n (%) 
Yes (grade ≥ 7) 22 (13%) NA NA NA NA
No (grade < 7) 141 (87%) NA NA NA NA
Significant fibrosis, n (%) 
Yes (F ≥ 3) 33 (20%) NA NA NA NA
No (F < 3) 130 (80%) NA NA NA NA
Abbreviations: ALK, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CHB, chronic hepatitis B; IQR, 
interquartile range; NA, not applicable; xULN, upper limit of the normal range.
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over other noninvasive markers further highlighted the 
intimate connection between CHB-associated inflammation 
and hepatocyte apoptosis.
The diagnostic value of CK 18 serum levels for the 
identification of significant inflammation in viral infection-
associated chronic liver disease corresponds well with the 
findings of Bae et al.21 This study reported a high specificity 
of 89% for CK 18 serum levels and a lower sensitivity of 45% 
for CHB patients, but also reported that the combination of 
CK 18 with AST yielded a much higher specificity up to 96% 
in their study, although simultaneously decreasing sensitivity 
to 38%.21 As a liver enzyme, AST is more representative of 
hepatocyte death in general rather as indicating hepatocyte 
apoptosis per se. In spite of a strong correlation between 
CK 18 and AST observed in our study, AST was not an 
Figure 1 Boxplots of serum CK 18 levels in relation with steatosis, inflammation, and fibrosis in in CHB patients. 
Notes: (A) No differences across grades of steatosis (P>0.05); (B) significant differences between significant and no significant inflammation (P<0.05); (C) significant 
differences between significant and no significant fibrosis (P<0.05).   
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Table 2 Correlation of clinical parameters with CK 18
Parameters ρ P-value
Age 0.04 0.603
BMI 0.11 0.183
ALT 0.52 <0.0001
AST 0.52 <0.0001
Albumin
-0.24 0.015
Viral load (log) 0.19 0.017
Steatosis 0.07 0.368
Inflammation 0.37 <0.0001
Fibrosis 0.18 0.020
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
BMI, body mass index.
Figure 2 Predictive value of CK 18 for significant inflammation.
Notes: We assessed the potential value of CK 18 as a diagnostic tool by estimating 
AUC, sensitivity, and specificity. The AUC of CK 18 for predicting significant 
inflammation was 0.81 (95% CI: 0.72–0.91).
Abbreviations: AUC, area under the curve; ROC, receiver operating characteristic.
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independent predictor, suggesting that hepatocyte apoptosis 
and necrosis is a defining property in CHB.
Considering significant fibrosis, CK 18 serum levels were 
previously reported as a useful predictor of this process in 
NAFLD patients,10,23 and a correlation of CK 18 serum levels 
with fibrosis stage in CHB is supported by the observations 
of Sumer et al.24 Similar to our findings, these authors detect 
increased CK 18 serum levels when significant fibrosis is 
present. Our data, however, indicate that CK 18 serum level 
cannot predict significant fibrosis independently, which also 
contrasts a recent study showing that CK 18 serum levels 
work independently as a predictor of the presence of sig-
nificant fibrosis (F ≥ 3).10 Generally speaking, we feel that 
hepatocyte apoptosis is unlikely to have a causal relation-
ship with the fibrosis process, and in potential agreement 
the Rosso et al’s study presented a low AUROC value (0.61) 
for fibrosis with a sensitivity of 88% and a specificity of 
38%.10 As a matter of fact, the beneficial role of apoptosis 
was ever reported in pancreatitis disease.33 Indeed, transient 
elastography,34 measuring liver stiffness, was found to be a 
better predictor than CK 18 serum levels. To obtain a more 
accurate prediction for the presence of significant fibrosis, 
both markers, transient elastography, and CK 18 serum levels 
were combined. Unfortunately, the combination performed 
not better than the transient elastography alone. In conclu-
sion, we feel that CK 18 may have only limited value for the 
identification of significant fibrosis.
Conclusion
Our study has further demonstrated the predictive value of 
CK 18 serum levels as a noninvasive marker for the presence 
of significant liver inflammation in CHB. In addition, the 
potential combination with other noninvasive markers might 
improve the total performance, especially the sensitivity. 
With regard to the identification of significant fibrosis, we 
considered the limited diagnostic value of CK 18. Further 
study is required to identify more reliable and efficient 
noninvasive tool. Finally, our results support the notion that 
hepatocyte apoptosis has an important functionality in CHB 
pathogenesis.
Disclosure
The authors report no conflicts of interest in this work.
Table 3 Performance of serum CK 18 levels for the diagnosis of significant inflammation and significant fibrosis
Parameter Cutoff value (U/L) Sensitivity (%) Specificity (%) PPV NPV LR+ LR–
Significant inflammation 243.0 68 82 37 94 3.9 0.4
Abbreviations: LR+, positive likelihood ratio; LR–, negative likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.
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